Loading
Nanoparticles / Vaccine Development / Vaccine Adjuvants · Journal article
Talanta · June 27, 2026
Raises a question worth testing. It does not answer one.
This is a bibliometric mapping study of next-generation adjuvant research from 2006–2025, analysing 8,637 publications to characterize global research structure, dominant themes, and analytical techniques. The work is descriptive and exploratory, identifying research trends (surge since 2020, mRNA-lipid nanoparticle focus) and technique landscape (single-cell RNA sequencing, proteomics, flow cytometry) rather than testing clinical efficacy or mechanistic hypotheses.
Bibliometric analysis with network and co-occurrence mapping. Publications on next-generation immunomodulatory adjuvants (NIAs) and advanced immune characterisation research indexed in Web of Science Core Collection and Scopus.. Intervention: Analysis of publication patterns, research themes, institutional collaborations, and analytical techniques in adjuvant immunology.. n = 8,637. Global analysis; United States and China identified as leading research hubs; Europe-Oceania noted as a major collaborative cluster..
8,637 unique publications retrieved from Web of Science Core Collection and Scopus and analysed using bibliometric, network, and co-occurrence approaches Sharp surge in research output since 2020 driven by mRNA-lipid nanoparticle vaccine development United States and China identified as dual global research hubs
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This mapping study does not directly inform clinical practice. It provides researchers and analytical chemists with a strategic roadmap of the adjuvant research landscape, emerging techniques, and research clusters, but does not evaluate the safety, efficacy, or clinical utility of any adjuvant or characterisation method.
A bibliometric analysis mapping research trends and technique landscapes; describes the field rather than testing a clinical hypothesis or intervention outcome.
As stated by the source record.
Quoted from the source exactly as published.
This mapping study does not directly inform clinical practice. It provides researchers and analytical chemists with a strategic roadmap of the adjuvant research landscape, emerging techniques, and research clusters, but does not evaluate the safety, efficacy, or clinical utility of any adjuvant or characterisation method.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study presents a comprehensive bibliometric analysis of next-generation immunomodulatory adjuvants (NIAs) and advanced immune characterisation research from 2006 to 2025, aiming to delineate the global landscape, thematic structure, and emerging frontiers in adjuvant immunology. A total of 8637 unique publications retrieved from the Web of Science Core Collection and Scopus were analysed using bibliometric, network, and co-occurrence approaches. The results show a sharp surge in research output since 2020, driven by mRNA-lipid nanoparticle vaccine development, with the United States and China emerging as dual global research hubs. Publications are distributed across five disciplinary domains centred on general/vaccine immunology, and institutional collaboration forms three major clusters dominated by the U.S., China, and Europe-Oceania respectively. Co-citation and keyword analyses reveal lipid nanoparticle/cGAS-STING signalling and mRNA vaccine/COVID-19 as the core mechanistic and translational axes. Advanced techniques including single-cell RNA sequencing, proteomics, and flow cytometry serve as critical bridges connecting adjuvant engineering to immune mechanism dissection. To our knowledge, this study represents the first systematic, data-driven mapping of the analytical technique landscape in next-generation adjuvant research. We uncover a previously unrecognised design-characterisation-mechanism-translation pipeline, revealing how advanced characterisation tools serve as the critical bridge between biomaterial engineering and immune mechanism dissection. These findings not only chart the intellectual structure of this rapidly expanding field but also provide a strategic roadmap for analytical chemists aiming to develop next-generation methodologies for adjuvant characterisation and programmable immunomodulation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.